Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Shineco Inc ($TYHT) stock jumped as the company announced its share exchange and acquisition agreement with strategic partner Western Xinjiang Tiansheng Agricultural Development Co., Ltd. The terms and conditions of the agreement provide for Xinjiang Shineco Taihe Agricultural Technology Ltd. to receive a 51% stake in Xinjiang Tiansheng in exchange for a 14% stake in Xinjiang Taihe plus three cash payments with an aggregate value of RMB23.8M or $3.57 million, contingent on certain milestones.
Shineco stock gained over 12 percent in its previous trading session, trimming its 12 months losses to 36 percent.

Intersect ENT Inc. ($XENT) reported the FDA approval for its SINUVA implant, designed to be used for treating recurrent nasal polyps in patients who have had previous ethmoid sinus surgery. The device delivers an anti-inflammatory steroid directly to the site of polyps, can be placed by a physician in an office setting. The FDA was expected to announce its decision on January 7, 2018.
The announcement sent the stock up by over 14 percent in its previous trading session. The stock has gained over 192 percent in the past 12 months and is now trading close to its 52 weeks high.


Merck ($MRK) announced the FDA approval for the review of its marketing application seeking approval for KEYTRUDA to treat adult and pediatric patients with refractory primary mediastinal B-cell lymphoma (PMBCL) who have relapsed after at least two prior lines of therapy. The agency's action date under Priority Review status has been set at April 3, 2018.
Regeneron Pharmaceuticals ($REGN) announced that the FDA has accepted for review its marketing application seeking approval for a 12-week dosing interval for EYLEA (aflibercept) Injection in patients with wet AMD. The drug is currently approved for eight-week dosing after three initial doses every four weeks.The FDA's action date (PDUFA) is August 11, 2018.

Eli Lilly announced that the FDA has accepted for review its marketing application seeking approval for galcanezumab for the prevention of migraine in adults. If approved, it will be available in an auto-injector pen or prefilled syringe.
Sanofi ($SNY) announced receiving the full approval from the FDA for its Admelog, a rapid-acting human insulin analog to improve glycemic control in adults and children with diabetes. The product was tentatively approved in September under the abbreviated 505(b)(2) pathway which allows the inclusion of data generated by others.


Allergan ($AGN) announced that it has agreed to acquire Repros Therapeutics ($RPRX) for $0.67 per share in cash. The acquisition price is almost at 43% premium to yesterday's close of $0.47.
Ionis Pharmaceuticals ($IONS) announced that Roche has exercised its option to license IONIS-HTTRx following the completion of a Phase 1/2a study of IONIS-HTTRx in people with Huntington's disease. Roche will now be responsible for all development and commercial activities.

Brokerage Company Name Rating Price
Target Impact on
Share Price Actions
BMO Capital Markets
Abbott Laboratories (ABT)
Market Perform -> Outperform Low

Credit Suisse Group
Alexion Pharmaceuticals (ALXN)
Buy $166.00 Low

Amgen (AMGN)
Buy $205.00 Low

Wells Fargo & Company
bluebird bio (BLUE)
Outperform $190.00 -> $242.00 Low

Dermira (DERM)
Buy $43.00 -> $39.00 Low

Robert W. Baird
Davita (DVA)
Neutral -> Outperform $63.00 -> $82.00 Low

Endo International (ENDP)
Neutral N/A
Epizyme (EPZM)
Buy $26.00 Low

Epizyme (EPZM)
Buy $26.00 Low

HC Wainwright
Fortress Biotech (FBIO)
Buy $11.00 N/A
Neutral -> Buy Low

Impax Laboratories (IPXL)
Buy N/A

Gainers (% price change) Last Trade Change Mkt Cap
Sunesis Pharmaceuticals SNSS 3.44 +0.96 (38.71%) 117.81M
Trinity Biotech plc (ADR) TRIB 5.49 +0.56 (11.36%) 131.98M
Kindred Healthcare, Inc. KND 8.55 +0.73 (9.27%) 743.27M
BioMarin Pharmaceutical BMRN 88.11 +6.12 (7.46%) 15.47B
Codexis, Inc. CDXS 7.20 +0.35 (5.11%) 348.10M
Losers (% price change)
Progenics Pharmaceuticals PGNX 5.64 -0.53 (-8.59%) 396.32M
MediciNova, Inc. MNOV 6.32 -0.56 (-8.14%) 228.16M
Rigel Pharmaceuticals RIGL 3.68 -0.30 (-7.54%) 539.09M
Seattle Genetics, Inc. SGEN 55.26 -3.99 (-6.74%) 7.95B
Sangamo Therapeutics Inc SGMO 15.85 -1.05 (-6.21%) 1.34B
Most Actives (dollar volume)
Celgene Corporation CELG 108.00 +1.91 (1.80%) 85.03B
Valeant Pharmaceuticals VRX 20.55 +0.85 (4.31%) 7.17B
Gilead Sciences, Inc. GILD 75.88 +1.66 (2.24%) 99.09B
Johnson & Johnson JNJ 141.14 +0.56 (0.40%) 379.18B
Merck & Co., Inc. MRK 56.34 +0.78 (1.40%) 153.66B